Dr. Stephen C. Greco

Samir Kanani is a Radiation Oncologist in Laurel, Maryland. Dr. Kanani is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. Dr. Kanani is currently accepting new patients.

Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Endoscopy.

Matthew Ladra, M.D., M.P.H., leads the dedicated pediatric team for the Johns Hopkins Proton Therapy Center and is the director of pediatric radiation oncology for the Johns Hopkins Kimmel Cancer Center, a clinical collaboration with Children’s National Hospital, where Dr. Ladra serves as faculty in the department of pediatric oncology. He is also an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins School of Medicine. Listen Dr. Ladra's Cancer Matters podcast episode to learn more about his work. Previously, Dr. Ladra served as the director of pediatric radiation at the Provision Center for Proton Therapy in Tennessee. He also completed a 2-year fellowship in pediatric proton therapy at the Massachusetts General Hospital’s Francis H. Burr Proton Center. Dr. Ladra is one of a handful of radiation oncologists whose research and clinical efforts focus exclusively on pediatric patients. He is frequently invited to speak on pediatric radiation oncology topics internationally and across the U.S. and has published extensively on the subject through original research book chapters and review articles. Dr. Ladra’s research efforts focus mainly on pediatric rhabdomyosarcoma treatment, early phase clinical trials involving radiation and non-chemotherapeutic agents, and reducing neurocognitive toxicity for pediatric brain tumor patients. LinkedIn https://www.linkedin.com/in/matthew-ladra-3094a316. Dr. Ladra is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Rhabdomyosarcoma, Muscle Invasive Bladder Cancer, Adult Soft Tissue Sarcoma, and Ependymoma.